Artiva Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

 

Artiva is prioritizing rheumatoid arthritis (RA) as the lead indication for its off-the-shelf NK cell platform and expects an H1 efficacy data readout in at least 15 RA patients (most with ≥6 months follow-up) alongside updates on potential pivotal-trial discussions with the FDA.


The therapy uses non‑genetically modified NK cells plus rituximab to drive deep B‑cell depletion and the company is targeting ~50% ACR50 in late-line RA; early autoimmunity data (32 patients) showed no CRS or ICANS and primarily transient cytopenias as the main safety signals.


Artiva says one cord unit can yield ~4 trillion NK cells (enough for ~500–1,000 patients) and its 9,000 sq ft facility could treat a similar scale, and the company reported $108 million in cash with runway into Q2 2027.
Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said during a discussion at the Needham Healthcare Conference. Speaking with Needham Senior Biotech Analyst Gil Blum, CEO Fred Aslan outlined the company’s mechanism of action, the upcoming clinical data catalyst in RA, and Artiva’s view of how safety, durability, and manufacturing scalability could shape adoption in community rheumatology settings.


https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-spotlights-ra-lead-220253762.html